Compare Extra Space Storage, Inc. (EXR) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Extra Space Storage, Inc. vs Spyre Therapeutics Inc. Common Stock — how do they compare? Extra Space Storage, Inc. trades at $135.18 (market cap $28.26B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.35B). The key difference: Extra Space Storage, Inc. is far larger — about 3.8× Spyre Therapeutics Inc. Common Stock's market cap, and Extra Space Storage, Inc. pays a 4.85% dividend while Spyre Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Extra Space Storage, Inc. for 109 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| EXR | SYRE | |
|---|---|---|
Market Cap | $28.26B | $7.35B |
Volume | 1,443,466 | 1,624,631 |
Sector | Real Estate | Health |
52-Week High | $152.85 | $108.92 |
52-Week Low | $126.67 | $22.18 |
Typical Hold Time | 109 Days | 0 Days |
Enterprise Value | $41.97B | $6.35B |
Dividend Yield | 4.85% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Extra Space Storage (EXR) trades at $133.74, down 0.23% today, with neutral technical signals and mixed analyst sentiment. The REIT shows strong fundamentals with consistent revenue growth from $3.3B (2024) to $3.4B (2025) and robust profitability (28.83% net margin). Recent quarters have seen earnings beats, with Q3 2026 results expected October 27, 2026. The company maintains solid operational performance with 94.2% same-store occupancy and recently announced leadership transition effective January 2027.
EXR presents a balanced risk-reward profile with 50% analyst buy ratings and $158.33 consensus price target (18% upside). Strengths include scale, diversified growth, and financial flexibility, while risks involve softer housing activity impact and elevated debt levels (46.63% debt-to-asset ratio). The stock offers income potential with $1.62 quarterly dividend, but investors should monitor interest rate sensitivity and competitive pressures in the self-storage sector.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Extra Space Storage, Inc.
Extra Space Storage is a fully integrated real estate investment trust that owns, operates, and manages almost 2,100 self-storage properties in 41 states, with over 160 million net rentable square feet of storage space. Of these properties, approximately one half is wholly owned, while some facilities are owned through joint ventures and others are owned by third parties and managed by Extra Space Storage in exchange for a management fee.
Read more on EXR →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
